A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome

Worawan B. Limpitikul, Ivy E. Dick, David J. Tester, Nicole J. Boczek, Pattraranee Limphong, Wanjun Yang, Myoung Hyun Choi, Jennifer Babich, Deborah Disilvestre, Ronald J. Kanter, Gordon F. Tomaselli, Michael J. Ackerman, David T. Yue

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Rationale: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca 2+ /calmodulin (CaM)-dependent inactivation of L-type Ca 2+ channels. Objective: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. Methods and Results: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca 2+ cycling properties, and (3) diminished Ca 2+ /CaM-dependent inactivation of L-type Ca 2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca 2+ /CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. Conclusions: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalCirculation Research
Volume120
Issue number1
DOIs
StatePublished - Jan 6 2017
Externally publishedYes

Fingerprint

Long QT Syndrome
Precision Medicine
Calmodulin
Induced Pluripotent Stem Cells
Clustered Regularly Interspaced Short Palindromic Repeats
Cardiac Myocytes
Action Potentials
Therapeutics
Mutation
Genes
Cardiac Arrhythmias
Alleles

Keywords

  • action potential
  • calmodulin
  • induced pluripotent stem cells
  • L-type calcium channels
  • long-QT syndrome
  • nucleotides

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Limpitikul, W. B., Dick, I. E., Tester, D. J., Boczek, N. J., Limphong, P., Yang, W., ... Yue, D. T. (2017). A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome. Circulation Research, 120(1), 39-48. https://doi.org/10.1161/CIRCRESAHA.116.309283

A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome. / Limpitikul, Worawan B.; Dick, Ivy E.; Tester, David J.; Boczek, Nicole J.; Limphong, Pattraranee; Yang, Wanjun; Choi, Myoung Hyun; Babich, Jennifer; Disilvestre, Deborah; Kanter, Ronald J.; Tomaselli, Gordon F.; Ackerman, Michael J.; Yue, David T.

In: Circulation Research, Vol. 120, No. 1, 06.01.2017, p. 39-48.

Research output: Contribution to journalArticle

Limpitikul, WB, Dick, IE, Tester, DJ, Boczek, NJ, Limphong, P, Yang, W, Choi, MH, Babich, J, Disilvestre, D, Kanter, RJ, Tomaselli, GF, Ackerman, MJ & Yue, DT 2017, 'A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome', Circulation Research, vol. 120, no. 1, pp. 39-48. https://doi.org/10.1161/CIRCRESAHA.116.309283
Limpitikul, Worawan B. ; Dick, Ivy E. ; Tester, David J. ; Boczek, Nicole J. ; Limphong, Pattraranee ; Yang, Wanjun ; Choi, Myoung Hyun ; Babich, Jennifer ; Disilvestre, Deborah ; Kanter, Ronald J. ; Tomaselli, Gordon F. ; Ackerman, Michael J. ; Yue, David T. / A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome. In: Circulation Research. 2017 ; Vol. 120, No. 1. pp. 39-48.
@article{a4762159ef494778a9fbaea88e8c2bc1,
title = "A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome",
abstract = "Rationale: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca 2+ /calmodulin (CaM)-dependent inactivation of L-type Ca 2+ channels. Objective: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. Methods and Results: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca 2+ cycling properties, and (3) diminished Ca 2+ /CaM-dependent inactivation of L-type Ca 2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca 2+ /CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. Conclusions: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.",
keywords = "action potential, calmodulin, induced pluripotent stem cells, L-type calcium channels, long-QT syndrome, nucleotides",
author = "Limpitikul, {Worawan B.} and Dick, {Ivy E.} and Tester, {David J.} and Boczek, {Nicole J.} and Pattraranee Limphong and Wanjun Yang and Choi, {Myoung Hyun} and Jennifer Babich and Deborah Disilvestre and Kanter, {Ronald J.} and Tomaselli, {Gordon F.} and Ackerman, {Michael J.} and Yue, {David T.}",
year = "2017",
month = "1",
day = "6",
doi = "10.1161/CIRCRESAHA.116.309283",
language = "English (US)",
volume = "120",
pages = "39--48",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT Syndrome

AU - Limpitikul, Worawan B.

AU - Dick, Ivy E.

AU - Tester, David J.

AU - Boczek, Nicole J.

AU - Limphong, Pattraranee

AU - Yang, Wanjun

AU - Choi, Myoung Hyun

AU - Babich, Jennifer

AU - Disilvestre, Deborah

AU - Kanter, Ronald J.

AU - Tomaselli, Gordon F.

AU - Ackerman, Michael J.

AU - Yue, David T.

PY - 2017/1/6

Y1 - 2017/1/6

N2 - Rationale: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca 2+ /calmodulin (CaM)-dependent inactivation of L-type Ca 2+ channels. Objective: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. Methods and Results: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca 2+ cycling properties, and (3) diminished Ca 2+ /CaM-dependent inactivation of L-type Ca 2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca 2+ /CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. Conclusions: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.

AB - Rationale: Calmodulinopathies comprise a new category of potentially life-threatening genetic arrhythmia syndromes capable of producing severe long-QT syndrome (LQTS) with mutations involving CALM1, CALM2, or CALM3. The underlying basis of this form of LQTS is a disruption of Ca 2+ /calmodulin (CaM)-dependent inactivation of L-type Ca 2+ channels. Objective: To gain insight into the mechanistic underpinnings of calmodulinopathies and devise new therapeutic strategies for the treatment of this form of LQTS. Methods and Results: We generated and characterized the functional properties of induced pluripotent stem cell-derived cardiomyocytes from a patient with D130G-CALM2-mediated LQTS, thus creating a platform with which to devise and test novel therapeutic strategies. The patient-derived induced pluripotent stem cell-derived cardiomyocytes display (1) significantly prolonged action potentials, (2) disrupted Ca 2+ cycling properties, and (3) diminished Ca 2+ /CaM-dependent inactivation of L-type Ca 2+ channels. Next, taking advantage of the fact that calmodulinopathy patients harbor a mutation in only 1 of 6 redundant CaM-encoding alleles, we devised a strategy using CRISPR interference to selectively suppress the mutant gene while sparing the wild-type counterparts. Indeed, suppression of CALM2 expression produced a functional rescue in induced pluripotent stem cell-derived cardiomyocytes with D130G-CALM2, as shown by the normalization of action potential duration and Ca 2+ /CaM-dependent inactivation after treatment. Moreover, CRISPR interference can be designed to achieve selective knockdown of any of the 3 CALM genes, making it a generalizable therapeutic strategy for any calmodulinopathy. Conclusions: Overall, this therapeutic strategy holds great promise for calmodulinopathy patients as it represents a generalizable intervention capable of specifically altering CaM expression and potentially attenuating LQTS-triggered cardiac events, thus initiating a path toward precision medicine.

KW - action potential

KW - calmodulin

KW - induced pluripotent stem cells

KW - L-type calcium channels

KW - long-QT syndrome

KW - nucleotides

UR - http://www.scopus.com/inward/record.url?scp=84994193768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994193768&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.116.309283

DO - 10.1161/CIRCRESAHA.116.309283

M3 - Article

VL - 120

SP - 39

EP - 48

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 1

ER -